Pharmaceutical - Cardio-vascular

Filter

Current filters:

Cardio-vascular

Popular Filters

1 to 25 of 432 results

Call for Indian govt to bring more essential drugs under price control from NGOs

Call for Indian govt to bring more essential drugs under price control from NGOs

22-08-2014

Non-governmental organizations in India have jointly issued a letter calling on the country’s government…

Cardio-vascularDiabetesIndiaNational Pharmaceuticals Pricing AuthorityPharmaceuticalPoliticsPricing

FDA expands indication for Eliquis to treatment of DVT and PE

FDA expands indication for Eliquis to treatment of DVT and PE

22-08-2014

US pharma majors Bristol-Myers Squibb and Pfizer late yesterday said that the US Food and Drug Administration…

Boehringer IngelheimCardio-vascularEliquisPfizerPharmaceuticalPulmonary embolismRegulationUSA

Russia’s Peptogen launches production of innovative CV drugs

Russia’s Peptogen launches production of innovative CV drugs

20-08-2014

Sergei Sobyanin, Mayor of Moscow, has officially launched a new Russian plant for the production of innovative…

Cardio-vascularHeart attacksMoscowPeptogenPharmaceuticalProductionRussiaSergey SobyaninStrogino

US DoJ closes investigation into AstraZeneca’s PLATO trial for Brilinta

US DoJ closes investigation into AstraZeneca’s PLATO trial for Brilinta

19-08-2014

Anglo-Swedish drug major AstraZeneca has received confirmation from the US Department of Justice that…

AstraZenecaBrilintaBrilintaCardio-vascularLegalPharmaceuticalUKUSA

Shares in Cytori fall as it announces suspension of heart disease trial

Shares in Cytori fall as it announces suspension of heart disease trial

07-08-2014

Shares in Cytori Therapeutics declined as much as 29% as it announced it was suspending enrollment in…

Cardio-vascularCytori TherapeuticsIschemic heart diseasePharmaceuticalResearchUSA

New indications approved in EU for Bristol-Myers/Pfizer Eliquis

New indications approved in EU for Bristol-Myers/Pfizer Eliquis

30-07-2014

The European Commission has approved US pharma majors Bristol-Myers Squibb and Pfizer’s Eliquis (apixaban)…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalRegulation

Sanofi and Regneron say Phase III alirocumab trials met primary endpoint

Sanofi and Regneron say Phase III alirocumab trials met primary endpoint

30-07-2014

French drug major Sanofi and USA-based biotech firm Regeneron Pharmaceuticals have announced that nine…

alirocumabCardio-vascularGeorge YancopoulosPharmaceuticalResearchSanofiUSA

Zealand and Boehringer link up to advance novel peptide medicines

Zealand and Boehringer link up to advance novel peptide medicines

28-07-2014

Denmark’s Zealand Pharma has entered into a new global exclusive licence and R&D collaboration with…

Boehringer IngelheimCardio-vascularDenmarkFinancialGermanyLicensingMetabolicsPharmaceuticalResearchZealand Pharma

Brazil and Mexico physicians’ preferences on anticoagulants

25-07-2014

Novel oral anticoagulants (NOACs) such as Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa…

BayerBoehringer IngelheimBrazilBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingMexicoPfizerPharmaceuticalPradaxaPricingXarelto

Resverlogix’s RVX-208 reduces major adverse cardiovascular events in diabetes mellitus patients

Resverlogix’s RVX-208 reduces major adverse cardiovascular events in diabetes mellitus patients

23-07-2014

Canadian clinical-stage cardiovascular specialist Resverlogix Corp has announced results it believes…

CanadaCardio-vascularDiabetesNephrology and HepatologyPharmaceuticalResearchResverlogixRVX-208

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

23-07-2014

The National Institute for Health and Care Excellence (NICE), the UK’s health care guidance body, has…

Acute coronary syndromesCardio-vascularEfientEli LillyPharmaceuticalprasugrelRegulationUK

Milestone appoints Francis Plat as chief medical officer

Milestone appoints Francis Plat as chief medical officer

21-07-2014

Quebec-based cardiovascular drug development specialist Milestone Pharmaceuticals has announced the appointment…

BoardroomCanadaCardio-vascularFrancis PlatMilestone PharmaceuticalsPharmaceutical

Servier to appeal EC fine over perindopril

Servier to appeal EC fine over perindopril

11-07-2014

French privately-held drugmaker Servier has said it will appeal before the European Union Court of Justice…

Cardio-vascularEuropeFinancialLegalPerindoprilperindoprilPharmaceuticalServier

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

10-07-2014

USA-based Portola Pharmaceuticals has entered into a second clinical collaboration agreement with Japanese…

andexanet alfaCardio-vascularDaiichi SankyoedoxabanJapanLicensingPharmaceuticalPortola PharmaceuticalsResearchSavaysaUSA

Proveca reaches agreement with EMA over heart failure drug for children

Proveca reaches agreement with EMA over heart failure drug for children

10-07-2014

UK pharmaceutical company Proveca has reached its fourth key agreement with the European Medicines Agency…

CaptoprilCardio-vascularPharmaceuticalRegulationUK

AstraZeneca in research accord with Max Planck Institute

AstraZeneca in research accord with Max Planck Institute

08-07-2014

Anglo-Swedish pharma major AstraZeneca has entered an agreement with the Max Planck Institute of Molecular…

AstraZenecaCardio-vascularMetabolicsPharmaceuticalResearch

Pozen re-files for US approval of PA8140/PA32540

Pozen re-files for US approval of PA8140/PA32540

02-07-2014

US drug firm Pozen has resubmitted the New Drug Application for PA8140/PA32540 (aspirin and omeprazole)…

AspirinCardio-vascularOmeprazolePA8140/PA32540PharmaceuticalPozenRegulationUSA

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP

27-06-2014

Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

FDA Breakthrough status for Boehringer’s investigational Pradaxa antidote

FDA Breakthrough status for Boehringer’s investigational Pradaxa antidote

26-06-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation to idarucizumab, an…

Boehringer IngelheimCardio-vascularidarucizumabPharmaceuticalPradaxaRegulationResearchUSA

FDA review of CV risks for diabetics taking olmesartan not conclusive

FDA review of CV risks for diabetics taking olmesartan not conclusive

25-06-2014

The US Food and Drug Administration has completed its safety review and has found no clear evidence of…

BenicarCardio-vascularDaiichi SankyoDiabetesolmesartanPharmaceuticalRegulationUSA

Third-party investigation confirms Takeda’s systematic involvement in CASE-J Study, but no data tampering

Third-party investigation confirms Takeda’s systematic involvement in CASE-J Study, but no data tampering

23-06-2014

Japan’s largest drugmaker Takeda Pharmaceuticals has updated on the third-party surrounding the results…

BlopressCardio-vascularJapanMarkets & MarketingPharmaceuticalResearchTakeda Pharmaceutical

Ivabradine and CV events in angina patients under review in Australia

Ivabradine and CV events in angina patients under review in Australia

23-06-2014

Australian pharma regulator the Therapeutic Goods Administration (TGA) is reviewing new information regarding…

AustraliaCardio-vascularCoralanivabradinePharmaceuticalRegulationServier

1 to 25 of 432 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top